Incannex Healthcare Inc.
IXHLDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
IXHL Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.13 | FQ end Jun/2026 | Call: tbd
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IHL-42X Low Dose | Phase 3 | Obstructive Sleep Apnea | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Incannex Healthcare Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Incannex Healthcare Inc.'s (IXHL) pipeline across Phase 3. Its lead program is IHL-42X Low Dose (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Incannex Healthcare Inc.'s next FDA catalyst?→
Incannex Healthcare Inc.'s (IXHL) next tracked catalyst is a Earnings expected October 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IXHL biotech catalysts?→
Add IXHL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Incannex Healthcare Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.